vs
Side-by-side financial comparison of AVITA Medical, Inc. (RCEL) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $17.6M, roughly 1.2× AVITA Medical, Inc.). Sight Sciences, Inc. runs the higher net margin — -20.4% vs -66.0%, a 45.6% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -4.3%). Sight Sciences, Inc. produced more free cash flow last quarter ($-2.0M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 2.9%).
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
RCEL vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.6M | $20.4M |
| Net Profit | $-11.6M | $-4.2M |
| Gross Margin | 81.2% | 87.3% |
| Operating Margin | -59.1% | -18.0% |
| Net Margin | -66.0% | -20.4% |
| Revenue YoY | -4.3% | 6.9% |
| Net Profit YoY | -0.3% | 64.9% |
| EPS (diluted) | $-0.37 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.6M | $20.4M | ||
| Q3 25 | $17.1M | $19.9M | ||
| Q2 25 | $18.4M | $19.6M | ||
| Q1 25 | $18.5M | $17.5M | ||
| Q4 24 | $18.4M | $19.1M | ||
| Q3 24 | $19.5M | $20.2M | ||
| Q2 24 | $15.2M | $21.4M | ||
| Q1 24 | $11.1M | $19.3M |
| Q4 25 | $-11.6M | $-4.2M | ||
| Q3 25 | $-13.2M | $-8.2M | ||
| Q2 25 | $-9.9M | $-11.9M | ||
| Q1 25 | $-13.9M | $-14.2M | ||
| Q4 24 | $-11.6M | $-11.8M | ||
| Q3 24 | $-16.2M | $-11.1M | ||
| Q2 24 | $-15.4M | $-12.3M | ||
| Q1 24 | $-18.7M | $-16.3M |
| Q4 25 | 81.2% | 87.3% | ||
| Q3 25 | 81.3% | 86.4% | ||
| Q2 25 | 81.2% | 84.8% | ||
| Q1 25 | 84.7% | 86.2% | ||
| Q4 24 | 87.6% | 86.8% | ||
| Q3 24 | 83.7% | 83.9% | ||
| Q2 24 | 86.1% | 85.8% | ||
| Q1 24 | 86.4% | 85.5% |
| Q4 25 | -59.1% | -18.0% | ||
| Q3 25 | -53.6% | -39.7% | ||
| Q2 25 | -60.5% | -59.6% | ||
| Q1 25 | -63.9% | -79.2% | ||
| Q4 24 | -54.1% | -62.5% | ||
| Q3 24 | -70.6% | -55.7% | ||
| Q2 24 | -102.8% | -59.2% | ||
| Q1 24 | -155.0% | -76.4% |
| Q4 25 | -66.0% | -20.4% | ||
| Q3 25 | -77.3% | -41.0% | ||
| Q2 25 | -53.9% | -61.0% | ||
| Q1 25 | -74.9% | -80.8% | ||
| Q4 24 | -63.0% | -62.1% | ||
| Q3 24 | -82.9% | -54.9% | ||
| Q2 24 | -101.3% | -57.7% | ||
| Q1 24 | -168.0% | -84.4% |
| Q4 25 | $-0.37 | $-0.07 | ||
| Q3 25 | $-0.46 | $-0.16 | ||
| Q2 25 | $-0.38 | $-0.23 | ||
| Q1 25 | $-0.53 | $-0.28 | ||
| Q4 24 | $-0.44 | $-0.23 | ||
| Q3 24 | $-0.62 | $-0.22 | ||
| Q2 24 | $-0.60 | $-0.25 | ||
| Q1 24 | $-0.73 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $-16.6M | $63.9M |
| Total Assets | $56.4M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $92.0M | ||
| Q3 25 | $23.3M | $92.4M | ||
| Q2 25 | $15.7M | $101.5M | ||
| Q1 25 | $25.8M | $108.8M | ||
| Q4 24 | $35.9M | $120.4M | ||
| Q3 24 | $44.4M | $118.6M | ||
| Q2 24 | $54.1M | $118.2M | ||
| Q1 24 | $68.2M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $-16.6M | $63.9M | ||
| Q3 25 | $-6.7M | $64.3M | ||
| Q2 25 | $-12.9M | $70.0M | ||
| Q1 25 | $-4.6M | $77.6M | ||
| Q4 24 | $4.5M | $87.5M | ||
| Q3 24 | $12.2M | $95.0M | ||
| Q2 24 | $23.9M | $101.6M | ||
| Q1 24 | $32.6M | $109.2M |
| Q4 25 | $56.4M | $115.3M | ||
| Q3 25 | $63.7M | $116.3M | ||
| Q2 25 | $58.1M | $122.0M | ||
| Q1 25 | $69.6M | $129.7M | ||
| Q4 24 | $79.7M | $142.8M | ||
| Q3 24 | $81.1M | $143.6M | ||
| Q2 24 | $87.8M | $149.7M | ||
| Q1 24 | $97.4M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.4M | $-1.8M |
| Free Cash FlowOCF − Capex | $-6.1M | $-2.0M |
| FCF MarginFCF / Revenue | -34.7% | -9.7% |
| Capex IntensityCapex / Revenue | 3.8% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-33.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.4M | $-1.8M | ||
| Q3 25 | $-5.2M | $-8.7M | ||
| Q2 25 | $-10.2M | $-7.5M | ||
| Q1 25 | $-10.3M | $-11.6M | ||
| Q4 24 | $-8.1M | $-3.5M | ||
| Q3 24 | $-7.2M | $362.0K | ||
| Q2 24 | $-12.8M | $-9.5M | ||
| Q1 24 | $-20.9M | $-9.8M |
| Q4 25 | $-6.1M | $-2.0M | ||
| Q3 25 | $-6.2M | $-8.9M | ||
| Q2 25 | $-10.8M | $-7.8M | ||
| Q1 25 | $-10.5M | — | ||
| Q4 24 | $-9.7M | $-3.6M | ||
| Q3 24 | $-11.0M | $311.0K | ||
| Q2 24 | $-15.4M | $-9.5M | ||
| Q1 24 | $-22.0M | $-9.9M |
| Q4 25 | -34.7% | -9.7% | ||
| Q3 25 | -36.1% | -44.7% | ||
| Q2 25 | -58.4% | -39.6% | ||
| Q1 25 | -56.9% | — | ||
| Q4 24 | -52.7% | -18.9% | ||
| Q3 24 | -56.1% | 1.5% | ||
| Q2 24 | -101.6% | -44.7% | ||
| Q1 24 | -198.2% | -51.4% |
| Q4 25 | 3.8% | 0.8% | ||
| Q3 25 | 5.5% | 0.9% | ||
| Q2 25 | 2.8% | 1.1% | ||
| Q1 25 | 1.2% | 0.0% | ||
| Q4 24 | 8.8% | 0.7% | ||
| Q3 24 | 19.2% | 0.3% | ||
| Q2 24 | 17.5% | 0.4% | ||
| Q1 24 | 10.3% | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RCEL
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
